Pioneering fully individualized TCR therapies for cancer
Our Mission
Neogene Therapeutics is a global, preclinical stage biotechnology company pioneering the development of next generation, fully individualized engineered T cell therapies for a broad spectrum of cancers.
Our proprietary neoantigen T cell receptor (TCR) discovery and T cell engineering platform identifies TCR genes with specificity for neoantigens – found exclusively on cancer cells as a result of cancer-associated DNA mutations.
Cancer is a genetically individual disease – no two tumors are exactly the same. These variations create neoantigens – unique targets for every tumor. Neogene’s novel approach delivers a tailored T cell therapy containing a unique set of specific TCR genes for each individual patient. Engineered into patient-derived T cells, these TCRs are directed toward neoantigens in tumor cells, with the goal of eliciting strong and durable responses in a variety of solid tumor indications.
While engineered T cell therapies have transformed the treatment paradigm for patients with hematologic malignancies, effective T cell therapy is limited for solid cancers. To truly revolutionize patient outcomes, we need a new approach to effectively treat and potentially cure solid cancers.
We believe that through a fully individualized approach using patient-specific TCRs to target neoantigens, engineered T cell therapy can become broadly accessible to these patients.
Carsten Linnemann, Ph.D., Chief Executive Officer
Our History
Neogene is built on the premise of innovation and novel paradigm-changing science to enable effective T-cell therapy of solid cancers.
-
September 2018
Founded in Amsterdam, the Netherlands, by world-class cell therapy experts Ton Schumacher, Ph.D. and Carsten Linnemann, Ph.D. to advance the development of neoantigen T cell therapies.
- May 2019
-
September 2020
Raised $110 million Series A financing from marquee group of investors, led by EcoR1, Jeito Capital and Syncona.
- October 2020
- September 2018
- September 2020
-
October 2020
Announced strategic partnership with Twist Bioscience to build synthetic TCR libraries.
- May 2021
-
September 2018
Founded in Amsterdam, the Netherlands, by world-class cell therapy experts Ton Schumacher, Ph.D. and Carsten Linnemann, Ph.D. to advance the development of neoantigen T cell therapies.
- May 2019
-
September 2020
Raised $110 million Series A financing from marquee group of investors, led by EcoR1, Jeito Capital and Syncona.
- October 2020
- September 2018
- September 2020
-
October 2020
Announced strategic partnership with Twist Bioscience to build synthetic TCR libraries.
- May 2021
Our Team
Neogene’s leadership team is comprised of world-leading TCR experts and cell therapy industry veterans with decades of oncology knowledge and experience, who hold a deep commitment to providing innovative therapies to patients with cancer.

Carsten Linnemann, Ph.D.
Chief Executive Officer

Brent Pfeiffenberger, Pharm.D., MBA
Chief Operating Officer

Han Lee, Ph.D.
Chief Financial Officer

Raphaël Rousseau, M.D, Ph.D.
Chief Medical Officer

Catherine Lee, J.D.
General Counsel

Christopher Wilfong, MBA
Chief Business Officer

David M. Tanen
Corporate Secretary

Sean Algeo, CPA
Treasurer and Corporate Controller

Kanti Thirumoorthy, Ph.D.
Senior Vice President, Technical Operations

Gavin M. Bendle, Ph.D.
Senior Vice President, Research and Development

Mauro P. Avanzi, M.D., Ph.D.
Vice President, Clinical Development

Arianne Perez Garcia, Ph.D.
Vice President, Translational Sciences

June Seymour, CPA
Vice President, Finance

Sunny Xie
Vice President, Biometrics

Stephanie Heintz, M.P.H
Executive Director, Head of Human Resources

Marisa Leonard
Vice President, Head of Business Development

David Lund, Ph.D.
Vice President, Intellectual Property

Harish Mundre
Vice President, Head of Information Technology

Sanne Weijzen
Vice President, Corporate Strategy and EU Operations
Our Team
2018
2019
2020
2021
2022
Our Board of Directors is comprised of healthcare investors, scientists, pharma industry veterans, and biotech entrepreneurs who have a deep understanding of and commitment towards the development of novel cell therapies in oncology. They assist in supporting our long-term scientific and strategic plans and aid in advancing our mission to transform cancer immunotherapy.

Franz B. Humer, Ph.D., MBA
Executive Chairman of the Board of Directors

Carsten Linnemann, Ph.D.
Chief Executive Officer

Rachel Mears
Board Member

Martin Murphy, Ph.D.
Board Member

Ton N.M. Schumacher, Ph.D.
Co-Founder

Caroline Stout
Board Member

David M. Tanen
Corporate Secretary

Katherine Wood
Board Member

Rajul Jain, M.D.
Board Member
Our Partners
Neogene has a broad strategic partnership with Twist Bioscience Corporation, a company offering high-quality synthetic DNA using its silicon platform. Together, we are leveraging Neogene’s proprietary expertise in targeting tumor neoantigens, mutated proteins found in cancer cells due to cancer-associated DNA mutations, and Twist’s DNA synthesis platform and product lines to develop personalized chimeric antigen receptor (CAR) T cell therapies and T cell receptor (TCR) therapies for patients with cancer.
Our Investors
Neogene’s vision is shared by an outstanding syndicate of marquee investors, who have a deep understanding of and commitment towards the development of novel cell therapies in oncology.







